|
Field Administration of Stroke Therapy - Magnesium (FAST-MAG) Trial Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for qualified medical advice, visits or professional assistance by using a real mD. We are not docs. Always confer with your physician about Field Administration of Stroke Therapy - Magnesium (FAST-MAG) Trial conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Field Administration of Stroke Therapy - Magnesium (FAST-MAG) Trial Clinical research trials and Field Administration of Stroke Therapy - Magnesium (FAST-MAG) Trial health trials occur in many of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectivity of new does drugs. The intent of the studies / undertakings is to resolve particular human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to detect remedies for all sorts of conditions, including Field Administration of Stroke Therapy - Magnesium (FAST-MAG) Trial. Field Administration of Stroke Therapy - Magnesium (FAST-MAG) Trial Clinical Trials and other clinical trials permit volunteers to obtain healthcare treatment alternatives before they are available to the masses. Most times the participants undergo professional assistance for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Field Administration of Stroke Therapy - Magnesium (FAST-MAG) Trial clinical trial. Test subjects typically receive the most expert healthcare available for their Field Administration of Stroke Therapy - Magnesium (FAST-MAG) Trial condition. Dangers are a reality, however, and may include more or frequent mD visits, healthcare dangers (perhaps life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "F" Clinical Trials Conditions > Field Administration of Stroke Therapy - Magnesium (FAST-MAG) Trial  Field Administration of Stroke Therapy - Magnesium (FAST-MAG) Trial
Field Administration of Stroke Therapy - Magnesium (FAST-MAG) Trial
For Condition: Cerebrovascular Accident
Status: Not yet recruiting
Sponsor(s): National Institute of Neurological Disorders and Stroke (NINDS) ,
Synopsis: The goal of this study is to evaluate the effectiveness and safety of field-initiated magnesium sulfate in improving the long-term functional outcome of patients with acute stroke.
Details: Stroke is the third leading cause of death and the leading cause of adult disability in the United States. Each year, more than 750,000 Americans suffer a symptomatic stroke. Currently, rt-PA is the only approved treatment for acute ischemic stroke; however, its usefulness is limited because most patients cannot reach medical attention within the necessary 3-hour time window. In addition, rt-PA cannot be given in the field because it is contraindicated for treatment of patients with brain hemorrhage. The purpose of this multi-center, randomized, double-blind trial is to demonstrate that paramedic initiation of the neuroprotective agent magnesium sulfate in the field is an effective and safe treatment for acute stroke. This study will analyze magnesium sulfate, an experimental therapy for stroke, versus placebo among ambulance-transported patients with acute stroke. This trial will also demonstrate that paramedics can safely, effectively, and rapidly start neuroprotective therapies for stroke.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control
Minimum Age/Maximum Age: 40 Years/95 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Suspected stroke identified by the Los Angeles Prehospital Stroke Screen - Age 40-95, inclusive - Last known well time within 2 hours of treatment initiation - Deficit present for >/= 15 minutes Exclusion Criteria: - Coma - Rapidly improving neurologic deficit - Pre-existing neurologic, psychiatric, or advanced systemic disease that would confound the neurological or functional outcome evaluations - SBP < 90 or > 220 - Known severe renal dysfunction (on dialysis or known chronic creatinine > 3.0) - Severe respiratory distress (O2 sat < 90% or respiratory rate < 12 or >/= 24) - Known second or third degree heart block with no pacemaker in place - Major head trauma in the last 24 hours - Recent stroke within prior 30 days - Patient unable to give informed consent and no available legally authorized representative to provide informed consent
Total Enrollment: 1298
Location and Contact Information:
Overall Study Official:
SidneyStarkman, , UCLA Stroke Center, co-Principal Investigator
The Clinical Coordinating Center is: UCLA School of Medicine, 710 Westwood Plaza
Los Angeles, California, 90095
United States
Jeffrey Saver 310-794-6379
Additional Information:
Study ID Numbers: R01NS44364;
Study Start Date: July 2003
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00059332
Other Cerebrovascular Accident Studies:
1. Automated Constraint-Induced Therapy for Restoring Movement after Stroke
2. Study of Abnormal Blood Clotting in Children with Stroke
3. Secondary Prevention of Small Subcortical Strokes (SPS3) Trial
4. Prevention of Cerebral Infarction in Sickle Cell Anemia - Comprehensive Sickle Cell Center
5. Infection and Cardiovascular Disease
Related Studies:
Other Cerebrovascular Accident Clinical Trials
Other California Clinical Trials
Other Los Angeles Clinical Trials
Field Administration of Stroke Therapy - Magnesium (FAST-MAG) Trial
|
|
|
|
|
|
|
|
